Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gertruida Kruger"'
Autor:
Shabir A Madhi, Dhayendre Moodley, Sherika Hanley, Moherndran Archary, Zaheer Hoosain, Umesh Lalloo, Cheryl Louw, Lee Fairlie, Leon Frederik Fouche, Mduduzi S L Masilela, Nishanta Singh, Coert Grobbelaar, Khatija Ahmed, Gabriella Benadé, Sutika Bhikha, As'ad Ebrahim Bhorat, Qasim Bhorat, Natasha Joseph, Keertan Dheda, Aliasgar Esmail, Sharne Foulkes, Ameena Goga, Aylin Oommen Jose, Gertruida Kruger, Dishiki J Kalonji, Natasha Lalloo, Johan J Lombaard, Anthonet Lombard Koen, Angelique Kany Luabeya, Rosie Mngqibisa, Friedrich G Petrick, Annah Pitsi, Michele Tameris, Asha Thombrayil, Pieter-Louis Vollgraaff, Shane Cloney-Clark, Mingzhu Zhu, Chijioke Bennett, Gary Albert, Emmanuel Faust, Joyce S Plested, Lou Fries, Andreana Robertson, Susan Neal, Iksung Cho, Greg M Glenn, Vivek Shinde
Publikováno v:
The Lancet HIV. 9:e309-e322
There is a paucity of data on COVID-19 vaccines in people living with HIV-1, who could be at increased risk of severe illness and death from COVID-19. We evaluated the safety and immunogenicity of a Matrix-M adjuvanted recombinant spike protein nanop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d8d893c0e2b2b3d55fb7b313b938586
https://doi.org/10.1016/s2352-3018(22)00041-8
https://doi.org/10.1016/s2352-3018(22)00041-8
Autor:
Jinal N. Bhiman, Simone I. Richardson, Bronwen E. Lambson, Prudence Kgagudi, Nonkululeko Mzindle, Haajira Kaldine, Carol Crowther, Glenda Gray, Linda-Gail Bekker, Vivek Shinde, Chijioke Bennett, Gregory M. Glenn, Shabir Madhi, Penny L. Moore, Anthonet Koen, Lee Fairlie, Leon Fouche, Qasim Bhorat, Keertan Dheda, Michele Tameris, Mduduzi Masilela, Zaheer Hoosain, Nishanta Singh, Sherika Hanley, Moherndran Archary, Cheryl Louw, Coert Grobbelaar, Umesh Lalloo, Natasha Joseph, Gertruida Kruger
The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies. The NVX-CoV2373 vaccine, a protein nanopart
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f20617718c04f1389485913a5c0f8788
https://doi.org/10.21203/rs.3.rs-2048259/v1
https://doi.org/10.21203/rs.3.rs-2048259/v1
Autor:
Mduduzi Lawrance Sandile Masilela, Sherika Hanley, Asha Thombrayil, As’ad E. Bhorat, Nazira Carrim-Ganey, Sutika Bhikha, Natasha Lalloo, Gary Albert, Filip Dubovsky, Mingzhu Zhu, Dhayendre Moodley, Friedrich G. Petrick, Gregory M. Glenn, Tulio de Oliveira, Vicky L Baillie, Joyce S. Plested, Emmanuel Faust, Lee Fairlie, Zaheer Hossain, Jonah J Lombaard, Shane Cloney-Clark, Aylin Oommen Jose, Umesh G. Lalloo, Shabir A. Madhi, Lou Fries, Moherndran Archary, Ameena Ebrahim Goga, Leon Fouche, Andreana Robertson, Gertruida Kruger, Coert Grobbelaar, Pieter-Louis Vollgraaff, Susan Neal, Anthonet Koen, Annah Pitsi, Sharne Foulkes, Angelique Kany Kany Luabeya, Iksung Cho, Aliasgar Esmail, Chijioke Bennett, Michele Tameris, Cheryl Louw, Rosie Mngqibisa, Nishanta Singh, Q E Bhorat, Keertan Dheda, Khatija Ahmed, Gabriella Benade, Vivek Shinde
BackgroundThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the Covid-19 pandemic. Evaluation of Covid-19 vaccine efficacy against SARS-CoV-2 variants is urgently needed to inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c27c2860e4552b6b30c4cd64d893011
https://doi.org/10.1101/2021.02.25.21252477
https://doi.org/10.1101/2021.02.25.21252477